Double protease inhibitor combinations.
D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D002986:Clinical Trials as Topic; D004279:DNA, Viral / Q000032:analysis; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008060:Lipodystrophy / Q000139:chemically induced; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use; D012367:RNA, Viral / Q000032:analysis; D013601:T-Lymphocytes / Q000821:virology; D019562:Viral Load
D019380:Anti-HIV Agents; D004279:DNA, Viral; D017320:HIV Protease Inhibitors; D019384:Nucleic Acid Synthesis Inhibitors; D012367:RNA, Viral; D006918:Hydroxyurea